Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream: Analysis of a US Payer Claims Database

EP: 1.Insights for Clinicians: Leveraging Real-World Data for Informed Practice

EP: 2.Real-World Clinical Experience With Ruxolitinib Cream Monotherapy to Manage Atopic Dermatitis

EP: 3.Treatment Transitions: Exploring Clinical Responses to Ruxolitinib Monotherapy for Atopic Dermatitis Management

Now Viewing

EP: 4.Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream: Analysis of a US Payer Claims Database

EP: 5.Mitigating Alternative Topical Treatments: Ruxolitinib's Role in Atopic Dermatitis Management

Video content above is prompted by the following question(s):

• How might conditions such as allergic rhinitis, anxiety, and asthma intersect with AD in terms of disease management and treatment response?
• Can you summarize the treatment patterns observed in this study before and after initiation of ruxolitinib cream, including the utilization of other topical and systemic therapies?
• Considering the baseline therapies used by patients prior to initiating ruxolitinib cream, does the distribution align with what you would expect in this patient population?
• Are there any specific patterns or trends in baseline therapy utilization that you find noteworthy or unexpected from this study?